Introduction
Proteasomes are intracellular, multisubunit and multicatalytic complexes which are responsible for the degradation of proteins and generation of peptides presented by the major histocompatibility complex (MHC) class I antigens to T cells (1, 2). The 20S proteasome or constitutive proteasome is composed of twenty-eight subunits arranged in four stacked seven-membered rings, with the outer two rings containing seven non-catalytic α subunits and the inner rings containing ten β subunits in humans (3). Three of the β subunits, delta (Y), MB1 (X) and Z are catalytic (4, 5) . When cells are incubated with interferon-γ (IFN-γ), delta (Y), MB1 (X) and Z subunits are replaced by low molecular weight protein (LMP)2, LMP7 and LMP10, respectively, leading to the replacement of constitutive proteasome with immunoproteasome (6, 7). Immunoproteasome generates a spectrum of antigenic peptides different from that produced by constitutive proteasome, since it generates peptides with increased affinity for HLA class I allospecificities and is not efficient in processing peptides derived from self-proteins (8, 9) . As a result the specificity of the cytotoxic T lymphocyte (CTL) immune response elicited by constitutive proteasome and immunoproteasome is different. Studies with LMP2 and LMP7 knock-out mice suggest that defects in immunoproteasome subunits affect the CTL repertoire (10, 11).
Proteasomes are localized in both nucleus and cytoplasm in all types of eukaryotic cells (12) . The constitutive proteasome subunits are evenly distributed throughout the nucleus and the cytoplasm in rat liver (13). In contrast, immunoproteasomes are enriched around the endoplasmic reticulum (ER) in the cytoplasm, where they can provide efficient transport of peptides from the site of generation into the lumen of the ER in rat liver and in cultured human cells (14) . LMP2 and LMP7 were observed in the nucleus, while delta (Y) was identified in both the nucleus and the cytoplasm in cultured human cells (15).
Only scanty information is available about the localization of constitutive proteasome and immunoproteasome subunits in human cells and about their distribution in human tissues.
The paucity of information we have described is due, at least in part, to the limited or lack of availability of mAb which detect constitutive proteasome and immunoproteasome subunits in tissues. Furthermore, in spite of their role in shaping the specificity of CTL immune response, the expression of constitutive proteasome and immunoproteasome subunits in dendritic cells under physiological and pathological conditions has been characterized only to a limited extent. Lastly, although defects in the antigen processing machinery in malignant cells have been documented, constitutive proteasome and immunoproteasome subunit expression has been analyzed in a limited number of malignant tumors and within each tumor in a limited number of lesions. Whether the phenotypes found in malignant lesions are normal or pathological cannot be determined in most of the cases because of lack of information about the phenotype of the corresponding normal tissues.
mAb represent the most reliable probes for this type of study, since conventional -5 -antisera suffer from the potential interference of contaminating antibodies and antibodies purified by affinity chromatography from antisera suffer from the practical difficulties to produce a large amount of this type of reagents. To the best of our knowledge, mAb specific for only some of the human constitutive proteasome and immunoproteasome subunits have been developed. They include the anti-delta (Y) mAb MCP421, the anti-Z mAb MCP168 (16), the anti-LMP2 mAb VF101-39F7 and VF101-39G5 (17), the anti-LMP7 mAb VF103-5D5 and VF103-8C2 (17). Among them mAb VF101-39F7, VF101-39G5, VF103-5D5 and VF103-8C2, which had been developed by one of us, stained both frozen and formalin-fixed tissues. However, these mAb are not available anymore, since the corresponding hybridomas have been lost. Whether mAb MCP421 and MCP168 are suitable for intracellular and immunohistochemical staining is not known.
To facilitate the analysis of constitutive proteasome and immunoproteasome subunit expression in normal tissues, and in pathological lesions we have developed and characterized mAb which react with these subunits in intracytoplasmic and immunohistochemical staining. The aim of this paper is to describe the immunization strategy and the characterization of the specificity and reactivity pattern of the panel of mAb we have developed.
Materials and Methods

Mice
Six to eight week old female BALB/c mice were bred and maintained in the Department of Laboratory Animal Resources at Roswell Park Cancer Institute (RPCI).
Cells and tissues
The mouse myeloma cell line P3-X63-Ag8.653, the human B lymphoid cell line LG2, the human LMP2 and LMP7 deficient lymphoblastoid cell line T2 (18) and the human melanoma cell line Colo 38 were cultured in RPMI 1640 medium (Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Bio-Whittaker, Walkersville, MD) in a 5% CO 2 atmosphere at 37°C.
A lymph node with no detectable pathological abnormalities was obtained from a patient who underwent surgery for therapeutic reasons. This lymph node was prepared and stored at -80°C in the Department of Pathology at RPCI. Esophageal mucosa with no detectable pathological abnormalities and primary esophageal carcinoma lesions were obtained from patients who underwent surgery at the Asahikawa Medical College Hospital, Asahikawa, Japan. Tissue samples were fixed with 20% buffered formalin, routinely processed, and embedded in paraffin.
Monoclonal and polyclonal antibodies and reagents
The anti-idiotypic mAb MK2-23 (IgG 1 ) used as an isotype negative control was developed as described (19) . Peroxidase-conjugated goat anti-mouse IgG (Fcγ fragment specific) antibodies were purchased from Jackson Immuno Research (West Grove, PA). R-phycoerythrin (RPE) and fluorescein isothiocyanate (FITC)-conjugated F(ab') 2 fragments of goat anti-mouse IgG antibodies were purchased from DAKO (Carpinteria, CA).
Recombinant human IFN-γ was purchased from Roche Applied Science (Indianapolis, IN).
Insert Table 1 here
Synthetic peptides
Synthetic peptides corresponding to amino acid sequence stretches in human delta (Y), MB1 (X), Z, LMP2, LMP7, LMP10 and β 2 -microglobulin (β 2 -m) were purchased from Louis, MO) using the coupling agent maleimidobenzoyl-N-hydroxysuccinimide (Pierce).
Insert Table 2 here
Oligonucleotide primers and recombinant fusion proteins
The oligonucleotide primers used for synthesis of delta (Y), MB1 (X), Z, LMP2, LMP7 and LMP10 cDNAs were purchased from Integrated DNA Technologies Inc. (Coralville, IA) and show in Table 2 . cDNA used to generate recombinant fusion proteins were cloned using pBAD/TOPO ® ThioFusion TM Expression system (Invitrogen, Carlsbad, CA) as described elsewhere (20). The recombinant fusion proteins were expressed and purified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to the manufacturer's instructions and used for immunization.
Generation of mAb secreting hybridomas
BALB/c mice were immunized with KLH-conjugated peptides (50-100 μg each) emulsified in Freund's complete adjuvant (Sigma) and an intraperitoneal injection of SDS-PAGE purified recombinant fusion protein (100-200 μl of gel suspension/injection) following the strategy previously described (20). Hybridization and subcloning were performed as described (21). Isotyping of mAb was performed utilizing IsoStrip (Roche Applied Science) following the manufacturer's protocol.
Binding assay with BSA-conjugated peptides
The enzyme-linked immunosorbent assay (ELISA) with peptides to determine peptide specific reactivity of sera from mice immunized with constitutive proteasome and immunoproteasome subunit-derived peptides and recombinant fusion proteins and of mAb was performed as described (22). Cell permeabilization, intracellular staining and flow cytometric analysis were performed as described elsewhere (23).
Immunochemical assay
Western blot analysis was performed as described (22).
Immunofluorescence analysis
Microscopic analysis of intracellularly stained cells was performed as described with minor modifications (14). Briefly, following fixation with -20°C absolute methanol for 10 min, cells were permeabilized by 30 min incubation with PBS containing 1% BSA and 0.1% saponin (Sigma) at 4°C. Then cells were sequentially incubated with an optimal amount of primary mAb and with FITC-conjugated F(ab') 2 fragments of goat anti-mouse IgG antibodies. Cells were then analyzed under a fluorescence microscope (MC80 microscope camera; Carl Zeiss, Thornwood, NY).
Immunohistochemical staining of frozen and formalin-fixed tissue section
Immunohistochemical staining of frozen and formalin-fixed, paraffin-embedded tissue sections with mAb was performed utilizing the Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA) and the EnVision+ system (DAKO), respectively, as described elsewhere (20). Insert Table 3 here
Results
Selection
Characterization of constitutive proteasome and immunoproteasome subunit-specific mAb
Characterization of proteasome subunit-specific mAb is shown in Table 3 . All proteasome subunit-specific mAb except mAb SJJ-3 displayed a dose dependent reactivity with the immunizing peptide in ELISA (Fig. 1 ). This reactivity is specific since all of the mAb did not react with a peptide derived from human β 2 -m and a peptide derived from an amino acid sequence stretch of each protein different from that used to synthesize the peptides -12 -used as immunogens. The specificity of the mAb was corroborated by their reactivity pattern with a lymphoid LG2 cell lysate in Western blotting (Fig. 2) . Flow cytometric analysis showed that the staining intensity of the human B lymphoid cells
LG2 with mAb SY-1, HB-2 and TO-7 was upregulated following incubation with IFN-γ, while that with mAb SY-5, SJJ-3 and NB-1 was downregulated slightly.
Insert were stained with constitutive proteasome and immunoproteasome subunit-specific mAb.
The staining was distributed both in nucleus and in cytoplasm when cells were stained with delta (Y)-specific mAb SY-5, MB1 (X)-specific mAb SJJ-3 and Z-specific mAb NB-1 (panels A, B and C, respectively). On the other hand, the staining was strong in the cytoplasm and weak in the nucleus, when cells were stained with LMP2-specific mAb SY-1, LMP7-specific mAb HB-2 and LMP10-specific mAb TO-7 (panels D, E and F, respectively).
Insert In the present study, we demonstrated the localization of constitutive proteasome and immunoproteasome subunits in human cultured cells stained with the six mAb. The anti-delta (Y) mAb SY-5, the anti-MB1 (X) mAb SJJ-3 and the anti-Z mAb NB-1 stained both cytoplasm and nucleus in human melanoma Colo 38 cells. In contrast, the anti-LMP2 mAb SY-1, the anti-LMP7 mAb HB-2 and the anti-LMP10 mAb TO-7 stained the cytoplasm strongly. The staining in the cytoplasm appeared to be associated with the ER. These data are in agreement with the report previously described about the -17 -localization of delta (Y), LMP2 and LMP7 in human cultured cells (15).
In immunohistochemical staining, the six mAb stained formalin-fixed, paraffin-embedded tissue sections. However, the six mAb with the exception of anti-LMP7 mAb HB-2 did not stain frozen tissue sections. This finding is not so surprising, since the selection of the immunogens used was determined by our emphasis on the development of mAb which react with proteasome subunits in formalin-fixed, paraffin-embedded tissue sections. We immunized with both recombinant proteins purified by SDS-PAGE and synthetic peptides selected from each proteasome subunit for their likely immunogenicity. These immunogens were selected, since they are likely to elicit antibodies reacting with determinants expressed on denatured proteins and therefore likely to be expressed in formalin fixed, paraffin embedded tissue sections. Fixation of tissues in formalin is likely to denature proteins and to change their antigenic profile.
The six mAb we have developed are expected to facilitate the characterization of constitutive proteasome and immunoproteasome subunit expression in normal tissues and in pathological lesions and the analysis of the localization of the subunits in human cells.
-18 - (lanes 1, 3, 5, 7, 10 and 13), a mouse myeloma cell line P3-X63-AG8.653 (lanes 2, 4, 6, 8, 11 and 14) and a human LMP2 and LMP7 deficient cell line T2 (lanes 9 and 12) were separated on 12% polyacrylamide gels under denaturing conditions. After a transfer procedure, membranes were incubated with an appropriate amount of delta (Y)-specific mAb SY-5 (lanes 1 and 2), MB1 (X)-specific mAb SJJ-3 (lanes 3 and 4), Z-specific mAb NB-1 (lanes 5 and 6), LMP2-specific mAb SY-1 (lanes 7 to 9), LMP7-specific mAb HB-2 (lanes 10 to 12) and LMP10-specific mAb TO-7 (lanes 13 and 14). Membranes were then incubated with peroxidase-conjugated goat anti-mouse IgG (Fc fragment-specific)
antibodies. After incubation with ECL Western blotting detection reagents, membranes
were exposed to Hyperfilm ECL. (X)-specific mAb SJJ-3 (panels B, E and H), Z-specific mAb NB-1 (panels C, F and I), LMP2-specific mAb SY-1 (panels J, M and P), LMP7-specific mAb HB-2 (panels K, N and -26 -Q) and LMP10-specific mAb TO-7 (panels L, O and R). Tissue sections were then incubated with Vectastain ABC or EnVision+ reagent. Staining was visualized using the liquid DAB substrate-chromogen system (×200). 
